BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Higher levels of omega-3, the healthy fat found in fish and nuts, were associated with better lung function and longer transplant-free survival. Could healthy fats found in nuts and fish slow the ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...

VIENNA — Treatment with a novel lysophosphatidic acid receptor 1 (LPA1) antagonist was associated with significant changes in baseline biomarkers of disease in adults with pulmonary fibrosis, based on ...